May 20, 2014 – Dr. L'Heureux to be the keynote speaker at the French National Meeting on Biomaterials Research ("Assises Nationales de la Recherche en Biomatériaux"; Autrans, France).
May 5, 2014 - Dr. McAllister to present Cytograft’s unique and successful business model at the Regenerative Medicine conference in San Francisco.  Program details can be found here.
April 27, 2014 – Dr. L'Heureux to present recent results regarding the use of "Cell-synthesized extracellular matrix particles for tissue engineering and aesthetic applications" at the Experimental Biology 2014 meeting in San Diego. Link to the published abstract in the FASEB Journal here.
April 25, 2014 - Dr. McAllister to present on the convergence of tissue engineering and bioprinting at the ISCT annual meeting. Meeting agenda is here.
March 16, 2014 – Dr. McAllister publishes a perspective manuscript in MedNous. Full text is available here.
March 14, 2014 – A patent application describing the new abdominal aorta aneurism (AAA) repair device created by Cytograft is published by the USPTO (Patent application 20140081385)
March 14, 2014 – Dr. L'Heureux to speak at the INSERM Workshop #226 "3D cell culture bridges the gap between cell culture and live tissue" (Bordeaux, France).
March 14, 2014 - Dr. McAllister presents data in an invited lecture at the Ohio State University wound Care Conference. Conference program can be found here.
October 28, 2013 – Dr. L’Heureux to hold a seminar at the Vascular Surgery Institute of Fudan University Medical School  (Shanghai, China). 
October 7, 2013 - Results from the "First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access" are published in the Journal of Vascular Surgery (available as Epub ahead of print). Link to publisher here.
December 5, 2013 - Drs. L’Heureux and McAllister publish in the 2012 World Stem Cell Report.  In this invited manuscript, Cytograft’s founders propose revised regulatory standards for autologous cell therapies.  See the full length manuscript in Regenerative Medicine here.
 
TISSUE ENGINEERED BLOOD VESSEL (TEBV)
Tissue Engineered Blood Vessel picture

Cytograft is able to produce vascular grafts made exclusively from the patient's own cells by rolling fibroblast (skin cells) sheets around temporary support mandrels. The sheets are created by culturing fibroblasts extracted from a small dermal biopsy taken from the patient. After maturation, the individual plies of the rolled sheet fuse to form a homogeneous tissue. The resulting vessels have the requisite mechanical properties to endure supra-physiological loads. To prevent thrombosis (blood clotting), the vessel's lumen is lined with the patient's endothelial cells extracted from a superficial vein biopsy. Both the skin and the vein biopsies are minimally invasive out-patient procedures.

LifeLine™ is a versatile technology that has the potential to be used for coronary bypass, as a peripheral graft for the prevention of lower limb amputation, or as an arterio-venous shunt for hemodialysis access. LifeLine™ has shown promising results in phase I/II clinical trials as reported in The New England Journal of Medicine and, most recently, the Lancet.

More information about LifeLine™ development stage is available in the pipeline section.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Lifeline™ graft is shown being sutured as an interpositional graft in the femoral artery.